Literature DB >> 10455175

Cloning and characterization of novel mouse and human secretory phospholipase A(2)s.

J Ishizaki1, N Suzuki, K Higashino, Y Yokota, T Ono, K Kawamoto, N Fujii, H Arita, K Hanasaki.   

Abstract

Mammalian secretory phospholipase A(2)s (sPLA(2)s) are classified into several groups according to molecular structure and the localization of intramolecular disulfide bridges. Among them, group IIA sPLA(2) has been thought to be one of the key enzymes in the pathogenesis of inflammatory diseases owing to its augmented expression under various inflammatory conditions. However, in a number of inbred mouse strains, the group IIA sPLA(2) gene is naturally disrupted by a frameshift mutation. Here, we report the cloning of a cDNA encoding a novel sPLA(2) expressed in the spleen of group IIA sPLA(2)-deficient mouse. We also cloned its human homolog and mapped its gene location on chromosome 1p36.12 near the loci of group IIA and V sPLA(2) genes. The human mature sPLA(2) protein consists of 125 amino acids (M(r) = 14,500) preceded by a 20-residue prepeptide and is most similar to group IIA sPLA(2) with respect to the number and positions of cysteine residues as well as overall identity (48%). Based on these structural properties, the novel sPLA(2) should be categorized into group II, called group IID to follow the already identified IIA to IIC sPLA(2)s. When the cDNA was expressed in COS-7 cells, PLA(2) activity preferentially accumulated in the culture medium. It is maximally active at neutral to alkaline pH and with 2 mM Ca(2+). In assays with individual substrates, L-alpha-1-palmitoyl-2-linoleoyl phosphatidylethanolamine was more efficiently hydrolyzed than the other phospholipids examined. An RNA blot hybridized with the cDNA exhibited two transcripts (2.0 and 1.0 kb) in human spleen, thymus, and colon. The expression of a novel sPLA(2) mRNA was elevated in the thymus after treatment with endotoxin in rats as well as in group IIA sPLA(2)-deficient mice, suggesting its functional role in the progression of the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455175     DOI: 10.1074/jbc.274.35.24973

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells.

Authors:  Caroline E von Allmen; Nicole Schmitz; Monika Bauer; Heather J Hinton; Michael O Kurrer; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Tim Sparwasser; Roger R Beerli; Martin F Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

2.  Interferon gamma-induced gene expression of the novel secretory phospholipase A2 type IID in human monocyte-derived macrophages is inhibited by lipopolysaccharide.

Authors:  John Lindbom; Anders G Ljungman; Christer Tagesson
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

3.  The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.

Authors:  R Newton; L Cambridge; L A Hart; D A Stevens; M A Lindsay; P J Barnes
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells.

Authors:  Seiko Masuda; Makoto Murakami; Michiko Mitsuishi; Kazuo Komiyama; Yukio Ishikawa; Toshiharu Ishii; Ichiro Kudo
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

5.  Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis.

Authors:  Barbara Balestrieri; Victor W Hsu; Huiya Gilbert; Christina C Leslie; Won K Han; Joseph V Bonventre; Jonathan P Arm
Journal:  J Biol Chem       Date:  2006-01-01       Impact factor: 5.157

6.  Cloning and recombinant expression of a structurally novel human secreted phospholipase A2.

Authors:  M H Gelb; E Valentin; F Ghomashchi; M Lazdunski; G Lambeau
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

7.  Nonbactericidal secreted phospholipase A2s are potential anti-inflammatory factors in the mammary gland.

Authors:  Eyal Seroussi; Shelly Klompus; Maayan Silanikove; Oleg Krifucks; Fira Shapiro; Arieh Gertler; Gabriel Leitner
Journal:  Immunogenetics       Date:  2013-10-03       Impact factor: 2.846

Review 8.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

9.  Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D.

Authors:  Yong-Xin Sun; Kazuhito Tsuboi; Yasuo Okamoto; Takeharu Tonai; Makoto Murakami; Ichiro Kudo; Natsuo Ueda
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

Review 10.  Harmful and protective roles of group V phospholipase A2: Current perspectives and future directions.

Authors:  Sachin K Samuchiwal; Barbara Balestrieri
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-10-08       Impact factor: 4.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.